China-based Changchun BCHT Biotechnology Co., Ltd (SHA: 688276) has announced that it has received clinical trial approval from the National Medical Products Administration (NMPA) for its human anti-tetanus toxin monoclonal antibody (mAb) A82/B86 injection combination preparation. This innovative treatment is designed as a prophylactic against tetanus.
Tetanus, a serious bacterial infection, can be effectively prevented through vaccination with a tetanus vaccine or by the injection of tetanus antitoxin or tetanus immunoglobulin. Notably, there are currently no monoclonal antibodies approved for this purpose in China.
The approval of the A82/B86 injection marks a significant advancement in the fight against tetanus, potentially offering a new preventive option in the healthcare landscape.-Fineline Info & Tech
